Nova-2 Inhibitors

The compounds listed above are indirect modulators affecting the splicing machinery, with which NOVA2 interacts. For instance, pladienolide B and its analogs target the spliceosome, the complex responsible for carrying out splicing of pre-mRNA in the nucleus. By inhibiting the spliceosome, these compounds could disrupt the alternative splicing events regulated by NOVA2. Sudemycins are another example of synthetic molecules affecting splicing, which could thereby have an effect on the splicing patterns influenced by NOVA2. Meanwhile, compounds like isoginkgetin and other pre-mRNA splicing inhibitors could impact the broader splicing landscape and indirectly modulate the function of NOVA2.

Even more indirectly, chloroquine affects RNA degradation and autophagy which can influence RNA turnover and might have secondary effects on RNA splicing and NOVA2's regulatory functions. Similarly, eukaryotic initiation factor inhibitors, like silvestrol, could affect translational control of spliced mRNAs and thus indirectly impact NOVA2's role in post-transcriptional gene regulation. The potential influence of these compounds on NOVA2 would require in-depth experimental validation, as their effects on RNA splicing are complex and could involve multiple pathways and mechanisms beyond NOVA2. Additionally, these compounds are likely to have broad effects on cellular function due to their impact on fundamental processes like RNA splicing and gene expression.